BRD4 antagonist-based therapy exerts lethal activity against FLT3 mutation expressing AML cells resistant to FLT3 tyrosine kinase inhibitors

被引：1
|
作者：
Rodriguez, Melissa [1 ]
Fiskus, Warren [1 ]
Sharma, Sunil [2 ]
Qi, Jun [3 ]
Schaub, Leasha J. [1 ]
Shah, Bhavin [1 ]
Devaraj, Santhana G. T. [1 ]
Liu, Ka [1 ]
Iyer, Swaminathan [1 ]
Bradner, James E. [3 ]
Bhalla, Kapil N. [1 ]
机构：
[1] Houston Methodist Res Inst, Houston, TX USA
[2] Huntsman Canc Inst, Salt Lake City, UT USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1721
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1721
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
    Parmar, Amanda
    Marz, Stefanie
    Rushton, Sally
    Holzwarth, Christina
    Lind, Katarina
    Kayser, Sabine
    Doehner, Konstanze
    Peschel, Christian
    Oostendorp, Robert A. J.
    Goetze, Katharina S.
    CANCER RESEARCH, 2011, 71 (13) : 4696 - 4706
  • [32] The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3
    Spiekermann, K
    Dirschinger, RJ
    Schwab, R
    Bagrintseva, K
    Faber, F
    Buske, C
    Schnittger, S
    Kelly, LM
    Gilliland, DG
    Hiddemann, W
    BLOOD, 2003, 101 (04) : 1494 - 1504
  • [33] Oncogenic CBL mutants have transforming potential in cells expressing the FLT3 tyrosine kinase.
    Reindl, Carola
    Vimpati, Sridhar
    Quentmeier, Hilmar
    Mellert, Gudrun
    Hiddemann, Wolfgang
    Spiekermann, Karsten
    BLOOD, 2006, 108 (11) : 419A - 419A
  • [34] The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML cells expressing a constitutively active FLT3.
    Spiekermann, K
    Dirschinger, RJ
    Schwab, R
    Faber, F
    Buske, C
    Schnittger, S
    Kelly, LM
    Gilliland, G
    Hiddemann, W
    BLOOD, 2002, 100 (11) : 34A - 34A
  • [35] CG'806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3.
    Zhang, Weiguo
    Zhang, Hongying
    Local, Andrea
    Rice, William G.
    Ly, Charlie J.
    Yu, Guopan
    Howell, Stephen B.
    Andreeff, Michael
    CLINICAL CANCER RESEARCH, 2017, 23 (24) : 49 - 50
  • [36] Sorafenib potently inhibits ETV6-PDGFRβ and FLT3 mutants,and shows activity against FLT3 mutants that are resistant to other small molecule inhibitors
    Lierman, E.
    Lahortiga, I.
    Van Miegroet, H.
    Mentens, N.
    Marynen, P.
    Cools, J.
    ACTA CLINICA BELGICA, 2007, 62 (04): : 251 - 251
  • [37] Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation
    Heng, Hao
    Zhi, Yanle
    Yuan, Haoliang
    Wang, Zhijie
    Li, Hongmei
    Wang, Shuxian
    Tian, Jieyi
    Liu, Haichun
    Chen, Yadong
    Lu, Tao
    Ran, Ting
    Lu, Shuai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 163 : 195 - 206
  • [38] KI2011 is a novel potent FLT3 tyrosine kinase inhibitor in acute myeloid leukemia cells with FLT3-mutation
    Ryu, Hwani
    Song, Jie-Young
    Ahn, Jiyeon
    CANCER RESEARCH, 2018, 78 (13)
  • [39] TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo
    Ma, Hayley
    Bao Nguyen
    Li, Li
    Greenblatt, Sarah
    Williams, Allen
    Zhao, Ming
    Levis, Mark
    Rudek, Michelle
    Duffield, Amy
    Small, Donald
    BLOOD, 2014, 123 (10) : 1525 - 1534
  • [40] Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML
    Carter, Bing Z.
    Mak, Po Yee
    Ruvolo, Vivian
    Tao, Wenjing
    Hughes, Paul
    Chen, Xiaoyue
    Morrow, P. K.
    Andreeff, Michael
    BLOOD, 2020, 136
12345